Plesner, T., Arkenau, H., Gay, F., Minnema, M. C., Boccadoro, M., Moreau, P., Cavenagh, J., Perrot, A., Laubach, J. P., Krejcik, J., Ahmadi, T., de Boer, C., Chen, D., Chiu, C., Schecter, J. M., & Richardson, P. G. (2019). enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study. British journal of haematology, 186, e35–e39. http://access.bl.uk/ark:/81055/vdc_100088130290.0x000060